Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Cell Genesys, Inc. (NasdaqNM:CEGE)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Reports
Location
342 Lakeside Drive
Foster City, CA 94404
Phone: (650) 425-4400
Fax: (650) 358-0803
Email: ir@cellgenesys.com
Employees (last reported count): 162
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 11%
·Over the last 6 months:
 · one insider sell; 1,000  shares
·Institutional: 49% (55% of float)
(187 institutions)
·Net Inst. Buying: 811.0K shares (+4.59%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Cell Genesys, Inc., a gene therapy company, is focused on the development and commercialization of cancer vaccines and gene therapies to treat major, life-threatening diseases. The Company is conducting multicenter clinical trials for its GVAX cancer vaccines in prostate cancer, lung cancer, pancreatic cancer and myeloma, and expects to initiate additional GVAX vaccine trials in many of these cancers, as well as leukemia, during 2001. GVAX vaccine for prostate and lung cancer are being developed through a worldwide collaboration with the pharmaceutical division of Japan Tobacco. In addition, Cell Genesys has a number of product opportunities at the preclinical stage, including in vivo gene therapies for cancer, hemophilia and cardiovascular disease. The Company's majority-owned subsidiary, Ceregene, Inc., is focused on the development of gene therapies for neurologic disorders. Cell Genesys also continues to hold a 10.5% equity ownership its former subsidiary, Abgenix, Inc.
More from Market Guide: Expanded Business Description

Financial Summary
Cell Genesys, Inc. is focused on the development and commercialization of gene therapies to treat cancer and other major, life-threatening diseases. For the six months ended 6/30/01, revenues rose 4% to $10 million. Net loss before accounting change totaled $4.9 million, vs. income of $136.1 million. Revenues reflect increased collaborative agreements. Loss reflects the absence of a $190.2 million realized gain on the sale of Abgenix stock.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Stephen Sherwin, M.D., 52
Chairman, CEO
$665K$2.1M
Joseph Vallner, Ph.D., 54
Pres, COO
385K--  
Matthew Pfeffer, 43
CFO, VP
238K--  
Christine McKinley, 47
VP of HR
236K1.5M
Dale Ando, M.D., 47
VP of Clinical Research
270K2.9M
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CEGEAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$11.75 
Recent Price$19.05 
52-Week High
on 25-Sep-2000
$33.063
Beta0.57 
Daily Volume (3-month avg)311.2K
Daily Volume (10-day avg)280.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-38.9%
52-Week Change
relative to S&P500
-18.1%
Share-Related Items
Market Capitalization$658.3M
Shares Outstanding34.6M
Float30.8M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$13.16 
Earnings (ttm)$0.78 
Earnings (mrq)-$0.14 
Sales (ttm)$0.71 
Cash (mrq)$18.38 
Valuation Ratios
Price/Book (mrq)1.45 
Price/Earnings (ttm)24.39 
Price/Sales (ttm)26.99 
Income Statements
Sales (ttm)$24.6M
EBITDA (ttm)-$20.1M
Income available to common (ttm)$29.4M
Profitability
Profit Margin (ttm)122.3%
Operating Margin (ttm)-92.1%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)4.01%
Return on Equity (ttm)4.82%
Financial Strength
Current Ratio (mrq)3.58 
Debt/Equity (mrq)0.00 
Total Cash (mrq)$635.0M
Short Interest
As of 8-Aug-2001
Shares Short1.39M
Percent of Float4.5%
Shares Short
(Prior Month)
1.37M
Short Ratio6.85 
Daily Volume203.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.